{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"48"}],"units":"Participants"}],"description":"Number of patients who withdrew the treatment due to adverse event","groups":[{"description":"Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate: Weeks 1-15:\n\n* 6 cycles of CHOP on Days 1 to 5, to be repeated q21 Days\n* Rituximab 375 mg/m2 on Day 0 or Day 1 of every CHOP cycle\n* IT chemoth:Depocyte 50 mg on Day 0 of cycles 2,3,4\\&5 of R-CHOP\n\nWeeks 18-22:\n\n• Methotrexate 1.5 g/m2 q14 Days x 2\n\nFrom Week 24:\n\n• Scrotal prophylactic radiotherapy or involved field radiotherapy(but can be planned concomitantly to R-CHOP in pts with bilateral disease)","id":"OG000","title":"R-CHOP, Depocyte, Methotrexate"},{"description":"Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate: Weeks 1-15:\n\n* 6 cycles of CHOP on Days 1 to 5, to be repeated q21 Days\n* Rituximab 375 mg/m2 on Day 0 or Day 1 of every CHOP cycle\n* IT chemoth:Depocyte 50 mg on Day 0 of cycles 2,3,4\\&5 of R-CHOP","id":"OG001","title":"R-CHOP + Lyposomal Cytarabine"},{"description":"Weeks 18-22:\n\n• Methotrexate 1.5 g/m2 q14 Days x 2","id":"OG002","title":"HD-MTX"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Weeks 1 -15 All patients treated with 6 cycles of R-CHOP (CHOP21) on days 0/1 to 5, to be repeated every 21 days Intratecal (IT) Chemotherapy: liposomal cytarabine on day 0 of cycles 2, 3, 4 and 5 of R-CHOP Weeks 18 - 22 High Dose (HD) Methotrexate (MTX) Days 0 - 4 of two 14 days cycles From Week 25 Scrotal prophylactic radio therapy (RT) to the contralateral testis.","reportingStatus":"POSTED","timeFrame":"From treatment start until the last drug administration, up to week 22 for the 'R-CHOP, Depocyte, Methotrexate' Group, up to 15 weeks (Weeks 1-15) for the 'R-CHOP + Lyposomal Cytarabine' Group, and from week 18-22 for the 'HD-MTX' Group","title":"Adverse Events Assessment","type":"PRIMARY","unitOfMeasure":"Participants"}